By H. Rand Scott, MD — Medical Director, Newport Pain Management  ·  Reviewed and updated July 2026

Fibromyalgia: The Complete Guide

In 1904, a British neurologist named Sir William Gowers coined the term "fibrositis" — Latin for inflammation of the fibrous tissues — to describe a condition of widespread body pain that didn't fit any known disease. The name stuck for seven decades, and it was completely wrong. There is no inflammation. There is no fibrous-tissue disease. When researchers finally looked closely with modern tools, they found the problem wasn't in the muscles at all — it was in how the nervous system was processing signals from them. In 1976 the condition was renamed fibromyalgia, "fiber-muscle-pain," but the underlying misconception — that this is somehow a disease of tissue rather than a disease of pain processing — still shapes how many doctors approach it today. That is one of the reasons fibromyalgia patients are, in my experience, the most likely of any chronic pain population to arrive at our office having been failed, dismissed, or mistreated by a long chain of prior providers.

First, the reassurance — and the framework

Three things to know at the outset.

First: fibromyalgia is real. It is not psychosomatic, not "somatization," not laziness or attention-seeking. Objective research over the past three decades — brain imaging, spinal-fluid chemistry, and small-fiber nerve studies — has demonstrated measurable, reproducible abnormalities in how the nervous system of a fibromyalgia patient handles ordinary sensory input. Anyone who tells you otherwise is behind the literature by twenty years.

Second: it is treatable. Not curable in most cases, but the difference between untreated fibromyalgia and well-managed fibromyalgia is enormous, and modern combination therapy achieves that difference far more often than any single drug or approach alone.

Third: getting the diagnosis right matters more here than in almost any other pain condition, because the wrong treatments actively make fibromyalgia worse. NSAIDs, steroid injections, and long-term opioids — the standard reach for most chronic pain — either fail outright or worsen the underlying nervous-system amplification. This is a condition where a good specialist's job is as much to protect the patient from the wrong treatment as to prescribe the right one.

What fibromyalgia actually is

At its core, fibromyalgia is a condition of central sensitization. The nervous system, for reasons still being unraveled, becomes hyperresponsive to sensory input from the body. Signals that would ordinarily register as light touch, mild stretch, or ordinary muscle work instead register as pain — and pain signals themselves are amplified, sometimes dramatically.

The condition typically emerges after a triggering event — physical trauma (whiplash injuries are notably associated), a serious infection, major surgery, or a period of severe psychological stress. There is a clear genetic predisposition; if a close relative has fibromyalgia, your risk is roughly eight times baseline. It occurs in women at roughly seven times the rate of men, though I believe the real ratio is closer to three or four to one — men are systematically underdiagnosed because the classical presentation described in textbooks is a woman's presentation, and men with the same underlying condition are more often labeled with "chronic pain syndrome," depression, or nothing at all.

The diagnosis — and how it's often missed

For thirty years, the diagnosis of fibromyalgia required a tender-point examination: pressing on eighteen defined body sites, counting how many hurt at a specified pressure, and requiring eleven of eighteen for a positive diagnosis. Those criteria were revised in 2010 and again in 2016, and the tender-point exam is no longer required. The current approach relies on two scored components — a Widespread Pain Index (which of nineteen body regions have hurt over the last week) and a Symptom Severity Scale (rating fatigue, unrefreshing sleep, and cognitive symptoms) — combined with a duration requirement of at least three months and the exclusion of other explanations.

The last part is critical. Fibromyalgia is what's called a diagnosis of pattern recognition and exclusion: several other conditions produce widespread pain and fatigue and must be ruled out before the label is applied. In our practice the standard workup includes thyroid studies (hypothyroidism can mimic fibromyalgia closely), rheumatologic screening (rheumatoid arthritis, lupus, and polymyalgia rheumatica can all present with widespread pain), Lyme disease serology in appropriate patients, vitamin D and B12 levels (both deficiencies produce diffuse musculoskeletal and neurological symptoms), and — often overlooked — an assessment for sleep apnea, which produces virtually identical fatigue and cognitive symptoms and coexists with fibromyalgia surprisingly often.

I would add one more entity to the differential that is not on most standard lists: mast cell activation syndrome (MCAS). MCAS produces flushing, GI symptoms, dysautonomia, and diffuse pain, and it overlaps clinically with fibromyalgia in ways most rheumatologists don't screen for. When a patient's fibromyalgia has prominent flushing, food reactivity, or histaminergic features, MCAS deserves a workup — because if it is present, treating it directly can substantially reduce the fibromyalgia burden.

The result of all this is that fibromyalgia patients see, on average, four to seven doctors before receiving the correct diagnosis, often over a period of years. That delay costs them opportunities for early intervention when the nervous-system amplification is most reversible.

The myth that hurts patients most

The imaging and biochemical evidence above is unambiguous: fibromyalgia patients process pain differently at a physiological level. That processing difference is not under conscious control any more than diabetes is. Being believed by a physician is not just a courtesy — it is, functionally, part of the treatment. The therapeutic relationship, and the sense that the pain is understood and taken seriously, has a measurable effect on outcomes.

The symptoms beyond pain

If fibromyalgia were only about pain it would be manageable. What makes it disabling for many patients is the constellation of related symptoms that accompany the pain.

Why the usual pain treatments fail

The medications that reliably help other chronic pain conditions have a track record in fibromyalgia that ranges from disappointing to counterproductive.

What actually works — medications

Three medications carry an FDA indication specifically for fibromyalgia: duloxetine (Cymbalta), milnacipran (Savella), and pregabalin (Lyrica). All three work upstream of the pain signal — modulating serotonin, norepinephrine, and calcium-channel activity in ways that reduce the nervous system's amplification. None cures fibromyalgia; all reduce symptom severity in a meaningful subset of patients.

Several off-label medications are equally important. Gabapentin — a medication I helped pioneer for pain use in the United States in the 1990s — is closely related to pregabalin, less expensive, often just as effective, and my usual first-line calcium-channel modulator. Low-dose amitriptyline at bedtime, 10 to 25 milligrams, addresses both pain and sleep and remains one of the best value-per-dollar medications in the entire field. Cyclobenzaprine, similarly, treats muscle tension and sleep together. Tramadol — another medication whose early use in pain management I helped establish — has weak opioid activity paired with SNRI activity and can be genuinely useful in fibromyalgia, though it must be dosed carefully in patients on other serotonergic drugs.

What actually works — beyond medications

Every honest fibromyalgia specialist will tell you the same thing: the best long-term outcomes come from patients who combine medication with sustained lifestyle work. The two most powerful non-medication interventions are aerobic exercise and sleep restoration.

The role of ketamine for refractory cases

Central sensitization is mediated in part by NMDA receptors in the spinal cord and brain. Ketamine is a potent NMDA-receptor blocker, and low-dose intravenous ketamine has emerged over the past decade as an option for fibromyalgia patients who have not responded adequately to the standard toolkit. The evidence base is smaller than for the FDA-approved medications, but growing, and the effect can be substantial for the right patient.

At Newport Pain Management we operate the KetaCure Ketamine Infusion Center specifically for patients whose chronic pain — including refractory fibromyalgia — has resisted other approaches. It is not a first-line treatment, and it is not appropriate for every patient. But for the subset who need it, it can be transformative, and it belongs in the conversation for anyone whose fibromyalgia has plateaued despite reasonable trials of the standard therapies. See our ketamine infusion FAQ for more detail.

Quality of life — the parts patients don't ask about

Fibromyalgia doesn't confine itself to the parts of life patients feel comfortable discussing at appointments. Intimacy is affected in most patients — through pain with position, through fatigue, and through medication side effects of the SNRIs used to treat the condition. This is a legitimate quality-of-life issue and worth raising at your visit; there are practical adjustments (timing medications, position modifications, dose changes) that often help.

Work and disability are the other large domain. Fibromyalgia is a leading cause of disability claims, and the interaction between employment, insurance systems, and symptom severity is complex. In my experience, patients who can maintain some structured work — even part-time, even modified — do better long-term than patients who withdraw completely. The structure itself is therapeutic. But that generalization does not apply to every patient, and pushing someone into work they cannot sustain is its own harm.

Family and relational strain is real. Fibromyalgia is largely invisible; family members may lack the reference point that visible illness provides, and the fluctuating nature of symptoms — a good day followed by a bad day — is genuinely confusing to people who haven't lived it. Educating the family, sometimes formally through a visit that includes them, is often as important as any prescription.

The bottom line

Fibromyalgia has been misunderstood by mainstream medicine for a hundred and twenty years, and the residue of that misunderstanding still shows up in how patients are treated. The current reality is more hopeful: it is a real condition of central pain amplification, it is diagnosable with modern criteria without ritual tender-point exams, and it responds — imperfectly but meaningfully — to a combination of the right medications, graded exercise, sleep restoration, and, for the right patients, advanced interventions like ketamine.

The essentials are: accurate diagnosis first, avoidance of the medications and interventions that make it worse, and patient combination therapy tailored to the individual. That is what we have been doing at Newport Pain Management since 1996. If you have fibromyalgia and feel your care has stalled, call us at (949) 759-8400.

This article is for general education and is not a substitute for individual medical advice.